Updates are available Correction dated 2019-07-10
Click to view Correction: https://doi.org/10.1007/s12281-019-00346-6
-
Authors
Jenks, Jeffrey D.
Spiess, Birgit
Buchheidt, Dieter
Hoenigl, Martin
-
Funding
Funding for this research was provided by:
Oesterreichische Nationalbank (Anniversary Fund, 15346)
- License Information
-
More Information
Article History
First Online: 20 June 2019
Change Date: 10 July 2019
Change Type: Correction
Change Details: Funding information was incomplete. The correct information is given below.
Compliance with Ethical Standards
:
: The funders had no role in the study design, data collection, analysis, interpretation, decision to publish, in the writing of the manuscript, or in the decision to submit the manuscript for publication.
: Dieter Buchheidt reports being a consultant to Basilea, Gilead Sciences, and Merck Sharp & Dohme/Merck; receiving research grants from Gilead Sciences and Pfizer; serving on the speakers’ bureau of Astellas, Basilea, Gilead Sciences, Merck Sharp & Dohme/Merck, Pfizer, and TEVA; and receiving travel grants from Astellas, Gilead Sciences, Merck Sharp & Dohme/Merck, and Pfizer. Martin Hoenigl reports untied research funding from Gilead. Jeffrey Jenks and Birgit Spiess declare no conflict of interest relevant to this manuscript.
: This article does not contain any studies with human or animal subjects performed by any of the authors.
